(Alliance News) - ImmuPharma PLC on Monday said its core anti-infective programme with antifungal and antibacterial candidates is progressing through pre-clinical studies, amid a narrowed loss. Read More
(Alliance News) - ImmuPharma PLC on Thursday announced "new discoveries" regarding the mechanism of action of its P140 autoimmune technology platform. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Thursday. Read More
ImmuPharma PLC - London-based specialist drug discovery and development company - Notes recent movements in its share price, as it has more than multiplied nearly five times higher in the last month to 6.03p per share, from 1.21p. The stock surged 94% higher in a single day in early January, to 2.33p, after ImmuPharma reported breakthrough findings in its preclinical research programme focused on P140 and the pathogenesis of autoimmune diseases. Read More
ImmuPharma PLC - London-based specialist drug discovery and development company - Says its preclinical research program focused on P140 and the pathogenesis of autoimmune diseases has yielded data that provides novel insights into autoimmune mechanisms. P140, the firms lead programme, is a unique non-immunosuppressive peptide for the treatment of systemic lupus erythematosus and chronic idiopathic demyelinating polyneuropathy. Adds that the findings, which were discovered by its R&D subsidiary ImmuPharma Biotech, pave the way for better diagnostics, identifying patients most likely to respond to P140 therapy and improved patient monitoring. Says the research marks a "significant step towards personalised medicine in SLE and other autoimmune diseases." Details of the data findings are not being released at this time since they form part of the ongoing expansion of the firms intellectual property portfolio. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Thursday. Read More
(Alliance News) - Stock prices in London made a largely uninspiring start to Thursday, amid a mixed response to Christmas trading statements from high streets, while the pound's descent continued. Read More
(Alliance News) - ImmuPharma PLC on Monday expressed optimism about the potential of its pipeline, after narrowing pretax loss in the first half. Read More
(Alliance News) - ImmuPharma PLC said on Monday it had extended its warrants in Incanthera PLC for the second time, valid now until March 31, 2025. Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - Immupharma PLC on Tuesday announced a new intellectual property strategy to significantly enhance the patent life and commercial value for its P140 technology platform. Read More
(Alliance News) - ImmuPharma PLC on Monday noted updates on Incanthera PLC's commercial skincare deal with Marionnaud, which was first announced in December 2023. Read More
(Alliance News) - Stock prices in London were down at midday on Monday, giving back some gains from last week, when equities were boosted by central bank decisions and accompanying statements which investors saw as dovish. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday. Read More
(Alliance News) - The following is a round-up of earnings and trading updates of London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
Incanthera PLC - develops technologies in dermatology and oncology - Raises GBP1.0 million in equity to support a deal that will see a major retailer stock Incanthera's 'Skin + Cell' range of skincare products. Raises GBP800,000 from the subscription to 11.4 million new shares at 7 pence each by new and existing institutional investors. At the same price, the University of Bradford converts GBP200,000 that is owed to it by Incanthera into 2.9 million new shares. The university, a founding shareholder in Incanthera, will own 11.2% of the enlarged share capital, with all the newly issued shares representing 15.5% of this. Incanthera also grants warrants to advisers to subscribe for another 800,000 new shares at the same price of 7p over the next 10 years. ImmuPharma PLC, which currently has a 12.7% stake in Incanthera, says it is "delighted" with the announcement of the skincare deal and successful fundraise. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - ImmuPharma PLC on Thursday announced a share placing and a retail share offer to raise just under GBP2 million, while it also reported a narrowed loss in the first half of the year on reduced expenses. Read More